In 1983, the identification of HIV, the virus responsible for AIDS, marked a grim era where contracting the virus was often considered a death sentence. Today, antiretroviral drugs have transformed the scenario, enabling people to manage the virus effectively, though a cure remains elusive. San Francisco-based biotech firm Excision BioTherapeutics aims to change that narrative with its groundbreaking gene-editing infusion, EBT-101.
Recent reports from the company have highlighted positive safety outcomes in the experimental drug’s one-off gene-editing treatment. The trial involved three patients, and no severe side-effects were observed. However, efficacy results are expected only by 2024, leaving anticipation for a potential breakthrough in the quest for an AIDS cure.
Continue reading… “Hope on the Horizon: Excision BioTherapeutics’ Crispr-Based Treatment for HIV Shows Promise”
